33 results on '"Popova, Vanina"'
Search Results
2. Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
3. Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL
4. Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
5. Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
6. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant
7. Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL
8. Road safety impact assessment practices and recommendations
9. A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics
10. F47. TRANSCRIPTIONAL PROFILING OF PERIPHERAL BLOOD IN DEPRESSIVE PATIENTS TREATED WITH ESKETAMINE NASAL SPRAY
11. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
12. 233. Transcriptional Profiling of Peripheral Blood in Depressive Patients Treated With Esketamine Nasal Spray
13. A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics
14. Additional file 1 of Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
15. Montgomery‐Åsberg Depression Rating Scale factors in treatment‐resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine
16. Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression
17. Farnesyl Protein Transferase Inhibitors in Pancreatic Cancer
18. Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression
19. Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
20. Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials
21. Comments to Drs. Bahji, Vazquez, and Zarate
22. Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials
23. Approval of esketamine for treatment-resistant depression
24. Comments to Drs. Gastaldon, Raschi, Kane, Barbui, and Schoretsanitis
25. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials
26. 175 Determining Meaningful Change in Depression Symptoms Assessed with PHQ-9 and SDS in Treatment-resistant Depression Trials of Esketamine Nasal Spray
27. 149 Evaluation of Individual Items on the PHQ-9 and SDS in Patients with Treatment-Resistant Depression Treated with Esketamine Nasal Spray
28. 119 Assessment of Health-Related Quality of Life and Health Status in Patients with Treatment-resistant Depression
29. Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui
30. Comment on a Word to the Wise About Intranasal Esketamine
31. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
32. S111. Randomized, Double-Blind Study of Flexibly-Dosed Intranasal Esketamine Plus Oral Antidepressant Vs. Active Control in Treatment-Resistant Depression
33. Comments to Drs. Gastaldon, Raschi, Kane, Barbui, and Schoretsanitis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.